Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases.

For both parameters, the clinical score and ankle thickening, the apparent difference between the two groups, however, did not reach statistical significance probably primarily due to the low magnitude of the therapeutic effect.

also in 111,027 other papers